Flagship Pioneering Unveils Laronde to Advance Endless RNA™ - A New Class of Programmable Medicines Capable of Expressing Therapeutic Proteins Inside the Body
- Endless RNA medicines are programmable, capable of producing persistent expression of therapeutic proteins inside the body, allow repeat redosing and multiple routes of administration
- Following three years of platform development, Flagship launches Laronde with $50 Million of committed capital. Laronde plans to rapidly scale its workforce and manufacturing capabilities to enable its bold vision of 100 new eRNA medicines and drug programs within the next decade
- Invented by a Flagship team led by Avak Kahvejian, Ph.D., Laronde co-founder, and Noubar Afeyan, Ph.D. co-founder and Chairman of Laronde; Diego Miralles, M.D., is Flagship Pioneering CEO-Partner and Chief Executive Officer of Laronde
CAMBRIDGE, Mass., May 10, 2021 /PRNewswire/ -- Flagship Pioneering today unveiled Laronde, a platform company developing Endless RNA™ (eRNA), a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body. Flagship initially committed $50 million to support the development of Laronde's platform and initial pipeline of new medicines.
eRNA technology was invented at Flagship Labs by a team led by Flagship Pioneering General Partner, Avak Kahvejian, Ph.D., who was also the founding CEO of Laronde. The company began in 2017 as FL50 (the 50th such life science platform developed within Flagship Labs) and has since operated as part of the broader Flagship enterprise. In 2017, the team began to explore the therapeutic applicability of long non-coding RNA (lncRNA), naturally abundant in circular form within mammalian cells. Unlike natural messenger RNA (mRNA), which initiates translation by recruiting ribosomes through interaction with proteins bound to the mRNA's 5' region, natural circular lncRNA does not readily interact with ribosomes. The Flagship team's exploration led to the invention of eRNA, a proprietary, closed-loop RNA construct engineered to be translatable. Having no free ends, eRNA are not recognized by the innate immune system or exonuclease enzymes, and are highly stable, enabling a prolonged therapeutic effect. In addition, the therapeutic protein expression capabilities of eRNA are modular and programmable. Switching the eRNA "protein-coding cassette" directs the body to make different peptides, enzymes, antibodies, channels, and receptors, both inside and outside of the cell.
"In the past decade, Flagship Labs has created multiple transformational companies based on programmable therapeutic modalities which allow for the more intentional and predictable creation of medicines," said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering, co-founder of Laronde, and Chairman of its Board of Directors. "With Endless RNA we have created a new class of medicines that can be programmed to persistently express therapeutic proteins in the body, at tunable levels, without generating an unwanted immune response, in a continuously redosable manner, with very simple delivery. The possible applications of this platform are very broad, with applications that have the potential to replace or augment many drug modalities currently in use."
Dr. Kahvejian added: "Flagship leveraged its unique combination of scientific expertise in RNA biology and experience building platforms to create and develop Laronde as the next breakthrough, multi-product platform company. eRNA therapeutics have the potential to be an essential and widespread class of medicines, expanding beyond small molecules and antibodies in their therapeutic applicability and utility. We can program eRNA medicines to code for a wide variety of therapeutic modalities." "We asked 'What if the circular nature of certain lncRNAs makes them ultra-stable in the body? Could we benefit from that stability to make a new class of therapeutic by making an RNA that has no free ends, but is translatable?' These insights led to our inventing and optimizing eRNA, to demonstrate its ability to generate prolonged protein expression in vitro and eventually in vivo, and to establishing a strong foundational IP estate around this new class of medicine."
In January, Dr. Diego Miralles joined Flagship Pioneering as CEO-Partner and assumed the role of CEO of Laronde. "This is a once-in-a-lifetime opportunity to join a company like Laronde, which will advance such a groundbreaking therapeutic platform capable of biological applications we could only dream of a few years ago," said Dr. Miralles. "Because the programmable platform is so scalable, we have the potential to parallel process the development of multiple programs at the same time that, if successful, could help millions of people around the world. We look forward to recruiting the best talent in the industry to build a great company that will fully realize the potential of eRNA."
To support the development and launch of multiple eRNA-based medicines, Laronde plans to build a modular and scalable eRNA Gigabase Factory to accommodate the clinical and commercial manufacture of up to 100 products and drug programs in the next 10 years. The company expects to hire more than 200 people over the next two years to support the advancement of its programs and platform.
About Laronde
Laronde is pioneering a platform that offers a completely novel way of modulating human biology. Endless RNA™ (eRNA), is a uniquely engineered RNA that can be programmed to express diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery. Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidly scaling to support the parallel development of multiple programs across many disease areas. To learn more, please visit the company's website at www.laronde.bio or Twitter and LinkedIn.
About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category life science platform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $80 billion in aggregate value. To date, Flagship has deployed over $2.3 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: AXLA), Codiak BioSciences (NASDAQ: CDAK) Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB), and Sigilon Therapeutics (NASDAQ: SGTX).
SOURCE Flagship Ventures
Share this article